Physician profile
Katherine E Dunham
NPI 1003579418
$1,069.59
in general payments reported to CMS, 2019-2025
14 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.16 · 2023: $201 · 2024: $470 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $208.39 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $184.39 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $177.23 | 2024-2025 | |
| Lilly USA, LLC | $113.27 | 2022-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.01 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $76.52 | 2024 | Rexulti |
| Glaxosmithkline, LLC. | $70.13 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Melinta Therapeutics, LLC | $32.49 | 2023-2025 | Orbactiv, Kimyrsa, Rezzayo |
| Collegium Pharmaceutical, INC. | $30.49 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $19.52 | 2024 | Voquezna |
| Pfizer INC. | $19.24 | 2023 | |
| Amgen INC. | $17.54 | 2025 | Evenity |
| Lundbeck LLC | $14.37 | 2023 | Rexulti |
| Phadia US INC. | $14.00 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.